CRISPR Is Curing Diseases, but Who Gets Access?

Photo by Sangharsh Lohakare on Unsplash

Imagine a world where a single medical treatment can end lifelong suffering from a genetic disease that once required constant hospital visits, pain management, and uncertainty. Thanks to the powerful gene-editing tool CRISPR, this world is no longer science fiction; it’s happening now. But as incredible as the science may be, a pressing question follows: Who actually gets to benefit?

At its core, CRISPR (short for clustered regularly interspaced short palindromic repeats) is a precision tool that allows scientists to edit DNA, the instruction manual of life. In the past few years, researchers and pharmaceutical companies have developed and received regulatory approval for CRISPR-based therapies that target two devastating inherited conditions: sickle cell disease and certain forms of inherited blindness.

One example is the gene-editing therapy known as Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics. This treatment works by extracting a patient’s own stem cells, editing the faulty genetic instructions that cause sickle cell disease, and then reinfusing the corrected cells into the patient’s body. In clinical trials and early use, this approach has significantly reduced painful, debilitating sickle cell episodes and offered what many doctors call a “functional cure” for patients who otherwise face a lifetime of pain and health complications.

Similarly, early clinical research into CRISPR therapies for inherited forms of blindness, where gene-editing molecules are delivered directly into retinal cells, has shown measurable improvements in vision for many patients. In one small study, the majority of treated individuals experienced detectable improvement in vision outcomes, offering hope that genetic eye diseases once considered untreatable might finally be addressed at their source.

Together, these breakthroughs represent a paradigm shift in medicine. Instead of simply managing symptoms with daily pills or lifelong therapies, CRISPR has the potential to fix the underlying genetic defects, a scientific milestone with enormous promise.

Yet as transformative as this technology is, its promise is not equally shared. One of the most glaring barriers to access is cost. Casgevy’s price tag in the U.S. hovers around $2.2 million per patient, and other gene therapies like Lyfgenia can cost even more. This astronomical price reflects years of research, the complexity of treatment (which functions almost like a bone marrow transplant), and the lack of cheaper alternatives. But it also raises fundamental questions of justice: should access to life-changing medicine depend on wealth, insurance coverage, or geographic location?

Even in countries with universal health systems like the United Kingdom, gene therapies have only been approved for a small number of patients each year, and healthcare authorities must weigh cost against budget constraints. In the United States, many patients with sickle cell disease rely on Medicaid, a program that often struggles with limited financial resources, meaning that eligibility for these treatments is uncertain for many who need them. There are other barriers, too. These treatments are not simple pills: they require specialized hospital centers, teams of highly trained specialists, and weeks of intensive care. Rural communities and less affluent regions often lack these resources, effectively placing advanced genetic medicine out of reach for much of the population.

Beyond economics, there are ethical concerns related to equity and historical mistrust. Sickle cell disease disproportionately affects Black communities in the United States and millions of people in sub-Saharan Africa. When cutting-edge therapies are developed without clear plans for equitable distribution or affordability, this can deepen distrust in medical institutions that have historically underserved these communities.

So what’s next? Advocates, policymakers, and some biotech leaders are pushing for innovative pricing models, expanded insurance coverage, and global collaborations to lower costs and widen access. But meaningful change will require not just scientific innovation, but political will, public pressure, and ethical commitment to ensure that the gene-editing revolution benefits everyone, not just those who can afford it. CRISPR’s potential to cure disease is real, but its promise won’t be fully realized until access is made equitable.